Rezdiffra

liver
Biotech

Madrigal pens $2B deal for CSPC's GLP-1, eyes Rezdiffra pairing

Madrigal is paying $120 million upfront for a preclinical GLP-1 agonist the biopharma plans to pair with its fatty liver disease med Rezdiffra.
James Waldron Jul 30, 2025 7:35am
proclaim red announcement

Aligos MASH prospect slashes liver fat in phase 2

Sep 19, 2024 1:00pm